Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations

  • Tiziana Lorenzini
  • Manfred Fliegauf
  • Nils Klammer
  • Natalie Frede
  • Michele Proietti
  • Alla Bulashevska
  • Nadezhda Camacho-Ordonez
  • Markku Varjosalo
  • Matias Kinnunen
  • Esther de Vries
  • Jos W M van der Meer
  • Rohan Ameratunga
  • Chaim M Roifman
  • Yael D Schejter
  • Robin Kobbe
  • Timo Hautala
  • Faranaz Atschekzei
  • Reinhold E Schmidt
  • Claudia Schröder
  • Polina Stepensky
  • Bella Shadur
  • Luis A Pedroza
  • Michiel van der Flier
  • Mónica Martínez-Gallo
  • Luis Ignacio Gonzalez-Granado
  • Luis M Allende
  • Anna Shcherbina
  • Natalia Kuzmenko
  • Victoria Zakharova
  • João Farela Neves
  • Peter Svec
  • Ute Fischer
  • Winnie Ip
  • Oliver Bartsch
  • Safa Barış
  • Christoph Klein
  • Raif Geha
  • Janet Chou
  • Mohammed Alosaimi
  • Lauren Weintraub
  • Kaan Boztug
  • Tatjana Hirschmugl
  • Maria Marluce Dos Santos Vilela
  • Dirk Holzinger
  • Maximilian Seidl
  • Vassilios Lougaris
  • Alessandro Plebani
  • Laia Alsina
  • Monica Piquer-Gibert
  • Angela Deyà-Martínez
  • Charlotte A Slade
  • Asghar Aghamohammadi
  • Hassan Abolhassani
  • Lennart Hammarström
  • Outi Kuismin
  • Merja Helminen
  • Hana Lango Allen
  • James E Thaventhiran
  • Alexandra F Freeman
  • Matthew Cook
  • Shahrzad Bakhtiar
  • Mette Christiansen
  • Charlotte Cunningham-Rundles
  • Niraj C Patel
  • William Rae
  • Tim Niehues
  • Nina Brauer
  • Jaana Syrjänen
  • Mikko R J Seppänen
  • Siobhan O Burns
  • Paul Tuijnenburg
  • Taco W Kuijpers
  • Klaus Warnatz
  • Bodo Grimbacher
  • UK NIHR BioResource Rare Diseases Consortium

Abstract

BACKGROUND: An increasing number of NFKB1 variants are being identified in patients with heterogeneous immunologic phenotypes.

OBJECTIVE: To characterize the clinical and cellular phenotype as well as the management of patients with heterozygous NFKB1 mutations.

METHODS: In a worldwide collaborative effort, we evaluated 231 individuals harboring 105 distinct heterozygous NFKB1 variants. To provide evidence for pathogenicity, each variant was assessed in silico; in addition, 32 variants were assessed by functional in vitro testing of nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) signaling.

RESULTS: We classified 56 of the 105 distinct NFKB1 variants in 157 individuals from 68 unrelated families as pathogenic. Incomplete clinical penetrance (70%) and age-dependent severity of NFKB1-related phenotypes were observed. The phenotype included hypogammaglobulinemia (88.9%), reduced switched memory B cells (60.3%), and respiratory (83%) and gastrointestinal (28.6%) infections, thus characterizing the disorder as primary immunodeficiency. However, the high frequency of autoimmunity (57.4%), lymphoproliferation (52.4%), noninfectious enteropathy (23.1%), opportunistic infections (15.7%), autoinflammation (29.6%), and malignancy (16.8%) identified NF-κB1-related disease as an inborn error of immunity with immune dysregulation, rather than a mere primary immunodeficiency. Current treatment includes immunoglobulin replacement and immunosuppressive agents.

CONCLUSIONS: We present a comprehensive clinical overview of the NF-κB1-related phenotype, which includes immunodeficiency, autoimmunity, autoinflammation, and cancer. Because of its multisystem involvement, clinicians from each and every medical discipline need to be made aware of this autosomal-dominant disease. Hematopoietic stem cell transplantation and NF-κB1 pathway-targeted therapeutic strategies should be considered in the future.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0091-6749
DOIs
StatusVeröffentlicht - 10.2020
PubMed 32278790